You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

SOVALDI Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Sovaldi patents expire, and what generic alternatives are available?

Sovaldi is a drug marketed by Gilead Sciences Inc and is included in two NDAs. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and sixty patent family members in forty-eight countries.

The generic ingredient in SOVALDI is sofosbuvir. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sofosbuvir profile page.

DrugPatentWatch® Generic Entry Outlook for Sovaldi

Sovaldi was eligible for patent challenges on December 6, 2017.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Drug patent expirations by year for SOVALDI
Drug Prices for SOVALDI

See drug prices for SOVALDI

Recent Clinical Trials for SOVALDI

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ain Shams UniversityPhase 3
Cairo UniversityPhase 3
Assiut UniversityEarly Phase 1

See all SOVALDI clinical trials

Pharmacology for SOVALDI
Paragraph IV (Patent) Challenges for SOVALDI
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SOVALDI Tablets sofosbuvir 400 mg 204671 2 2017-12-06

US Patents and Regulatory Information for SOVALDI

SOVALDI is protected by nine US patents and five FDA Regulatory Exclusivities.

Patents protecting SOVALDI

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Nucleoside phosphoramidates
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Nucleoside phosphoramidates
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Compositions and methods for treating hepatitis C virus
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Nucleoside phosphoramidates
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Compositions and methods for treating hepatitis C virus
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

FDA Regulatory Exclusivity protecting SOVALDI

FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
Exclusivity Expiration: ⤷  Try a Trial

FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
Exclusivity Expiration: ⤷  Try a Trial

PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷  Try a Trial

FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
Exclusivity Expiration: ⤷  Try a Trial

TREATMENT OF CHRONIC HCV GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead Sciences Inc SOVALDI sofosbuvir TABLET;ORAL 204671-001 Dec 6, 2013 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Gilead Sciences Inc SOVALDI sofosbuvir TABLET;ORAL 204671-002 Aug 28, 2019 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Gilead Sciences Inc SOVALDI sofosbuvir TABLET;ORAL 204671-001 Dec 6, 2013 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Gilead Sciences Inc SOVALDI sofosbuvir TABLET;ORAL 204671-002 Aug 28, 2019 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for SOVALDI

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Gilead Sciences Ireland UC Sovaldi sofosbuvir EMEA/H/C/002798
Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.
Authorised no no no 2014-01-16
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for SOVALDI

When does loss-of-exclusivity occur for SOVALDI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Patent: 15
Estimated Expiration: ⤷  Try a Trial

Argentina

Patent: 0819
Estimated Expiration: ⤷  Try a Trial

Patent: 0870
Estimated Expiration: ⤷  Try a Trial

Patent: 1813
Estimated Expiration: ⤷  Try a Trial

Patent: 2937
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 10249481
Estimated Expiration: ⤷  Try a Trial

Patent: 11235044
Estimated Expiration: ⤷  Try a Trial

Patent: 11235112
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 1012781
Estimated Expiration: ⤷  Try a Trial

Patent: 2012024884
Estimated Expiration: ⤷  Try a Trial

Patent: 2012024923
Estimated Expiration: ⤷  Try a Trial

Patent: 2013004621
Estimated Expiration: ⤷  Try a Trial

Patent: 2013007556
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 63151
Estimated Expiration: ⤷  Try a Trial

Patent: 94669
Estimated Expiration: ⤷  Try a Trial

Patent: 94671
Estimated Expiration: ⤷  Try a Trial

Patent: 19700
Estimated Expiration: ⤷  Try a Trial

Patent: 49694
Estimated Expiration: ⤷  Try a Trial

Patent: 15187
Estimated Expiration: ⤷  Try a Trial

Patent: 88217
Estimated Expiration: ⤷  Try a Trial

Patent: 77960
Estimated Expiration: ⤷  Try a Trial

Chile

Patent: 10000520
Estimated Expiration: ⤷  Try a Trial

Patent: 11000716
Estimated Expiration: ⤷  Try a Trial

Patent: 11000717
Estimated Expiration: ⤷  Try a Trial

Patent: 11000718
Estimated Expiration: ⤷  Try a Trial

Patent: 13000903
Estimated Expiration: ⤷  Try a Trial

Patent: 13000904
Estimated Expiration: ⤷  Try a Trial

China

Patent: 2459299
Estimated Expiration: ⤷  Try a Trial

Patent: 2858790
Estimated Expiration: ⤷  Try a Trial

Patent: 2906102
Estimated Expiration: ⤷  Try a Trial

Patent: 4017020
Estimated Expiration: ⤷  Try a Trial

Patent: 4292256
Estimated Expiration: ⤷  Try a Trial

Patent: 5085592
Estimated Expiration: ⤷  Try a Trial

Patent: 5198949
Estimated Expiration: ⤷  Try a Trial

Colombia

Patent: 70789
Estimated Expiration: ⤷  Try a Trial

Patent: 30166
Estimated Expiration: ⤷  Try a Trial

Patent: 30167
Estimated Expiration: ⤷  Try a Trial

Costa Rica

Patent: 120532
Estimated Expiration: ⤷  Try a Trial

Patent: 120534
Estimated Expiration: ⤷  Try a Trial

Croatia

Patent: 0151075
Estimated Expiration: ⤷  Try a Trial

Patent: 0160958
Estimated Expiration: ⤷  Try a Trial

Patent: 0171267
Estimated Expiration: ⤷  Try a Trial

Cyprus

Patent: 16976
Estimated Expiration: ⤷  Try a Trial

Patent: 18045
Estimated Expiration: ⤷  Try a Trial

Patent: 19273
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 32792
Estimated Expiration: ⤷  Try a Trial

Patent: 52930
Estimated Expiration: ⤷  Try a Trial

Patent: 09923
Estimated Expiration: ⤷  Try a Trial

Ecuador

Patent: 12012282
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 6341
Estimated Expiration: ⤷  Try a Trial

Patent: 6731
Patent: 1-МЕТИЛЭТИЛОВЫЙ СЛОЖНЫЙ ЭФИР N-[(2'R)-2'-ДЕЗОКСИ-2'-ФТОР-2'-МЕТИЛ-Р-ФЕНИЛ-5'-УРИДИЛ]-L-АЛАНИНА И СПОСОБ ЕГО ПОЛУЧЕНИЯ (N-[(2'R)-2'-DEOXY-2'-FLUORO-2'-METHYL-P-PHENYL-5'-URIDYLYL]-L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION)
Estimated Expiration: ⤷  Try a Trial

Patent: 8709
Patent: 1-МЕТИЛЭТИЛОВЫЙ СЛОЖНЫЙ ЭФИР N-[(2'R)-2'-ДЕЗОКСИ-2'-ФТОР-2'-МЕТИЛ-Р-ФЕНИЛ-5'-УРИДИЛ]-L-АЛАНИНА И СПОСОБ ЕГО ПОЛУЧЕНИЯ (N-[(2'R)-2'-DEOXY-2'-FLUORO-2'-METHYL-p-PHENYL-5'-URIDYL]-L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR PRODUCTION THEREOF)
Estimated Expiration: ⤷  Try a Trial

Patent: 8742
Estimated Expiration: ⤷  Try a Trial

Patent: 1171417
Patent: 1-МЕТИЛЭТИЛОВЫЙ СЛОЖНЫЙ ЭФИР N-[(2'R)-2'-ДЕЗОКСИ-2'-ФТОР-2'-МЕТИЛ-Р-ФЕНИЛ-5'-УРИДИЛ]-L-АЛАНИНА И СПОСОБ ЕГО ПОЛУЧЕНИЯ
Estimated Expiration: ⤷  Try a Trial

Patent: 1290988
Estimated Expiration: ⤷  Try a Trial

Patent: 1290993
Estimated Expiration: ⤷  Try a Trial

Patent: 1370186
Patent: 1-МЕТИЛЭТИЛОВЫЙ СЛОЖНЫЙ ЭФИР N-[(2'R)-2'-ДЕЗОКСИ-2'-ФТОР-2'-МЕТИЛ-P-ФЕНИЛ-5'-УРИДИЛ]-L-АЛАНИНА И СПОСОБ ЕГО ПОЛУЧЕНИЯ
Estimated Expiration: ⤷  Try a Trial

Patent: 1592101
Patent: 1-МЕТИЛЭТИЛОВЫЙ СЛОЖНЫЙ ЭФИР N-[(2'R)-2'-ДЕЗОКСИ-2'-ФТОР-2'-МЕТИЛ-Р-ФЕНИЛ-5'-УРИДИЛ]-L-АЛАНИНА И СПОСОБ ЕГО ПОЛУЧЕНИЯ
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 32792
Estimated Expiration: ⤷  Try a Trial

Patent: 52930
Estimated Expiration: ⤷  Try a Trial

Patent: 52931
Estimated Expiration: ⤷  Try a Trial

Patent: 52933
Estimated Expiration: ⤷  Try a Trial

Patent: 09923
Estimated Expiration: ⤷  Try a Trial

Patent: 10264
Estimated Expiration: ⤷  Try a Trial

Patent: 52422
Estimated Expiration: ⤷  Try a Trial

Patent: 10562
Estimated Expiration: ⤷  Try a Trial

Patent: 13337
Estimated Expiration: ⤷  Try a Trial

Patent: 90428
Estimated Expiration: ⤷  Try a Trial

Patent: 21275
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 69414
Estimated Expiration: ⤷  Try a Trial

Patent: 78171
Estimated Expiration: ⤷  Try a Trial

Patent: 81775
Estimated Expiration: ⤷  Try a Trial

Patent: 99645
Estimated Expiration: ⤷  Try a Trial

Patent: 13571
Estimated Expiration: ⤷  Try a Trial

Patent: 13572
Estimated Expiration: ⤷  Try a Trial

Patent: 17494
Estimated Expiration: ⤷  Try a Trial

Patent: 19106
Estimated Expiration: ⤷  Try a Trial

Patent: 51578
Estimated Expiration: ⤷  Try a Trial

Patent: 54977
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 26235
Estimated Expiration: ⤷  Try a Trial

Patent: 31637
Estimated Expiration: ⤷  Try a Trial

Patent: 34239
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 6492
Estimated Expiration: ⤷  Try a Trial

Patent: 2099
Estimated Expiration: ⤷  Try a Trial

Patent: 2174
Estimated Expiration: ⤷  Try a Trial

Patent: 7471
Estimated Expiration: ⤷  Try a Trial

Patent: 9115
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 72539
Estimated Expiration: ⤷  Try a Trial

Patent: 85659
Estimated Expiration: ⤷  Try a Trial

Patent: 09535
Estimated Expiration: ⤷  Try a Trial

Patent: 58528
Estimated Expiration: ⤷  Try a Trial

Patent: 06716
Estimated Expiration: ⤷  Try a Trial

Patent: 55605
Estimated Expiration: ⤷  Try a Trial

Patent: 12527477
Estimated Expiration: ⤷  Try a Trial

Patent: 13523767
Estimated Expiration: ⤷  Try a Trial

Patent: 13525277
Estimated Expiration: ⤷  Try a Trial

Patent: 13527145
Estimated Expiration: ⤷  Try a Trial

Patent: 15028060
Estimated Expiration: ⤷  Try a Trial

Patent: 15205903
Estimated Expiration: ⤷  Try a Trial

Patent: 16053045
Estimated Expiration: ⤷  Try a Trial

Lithuania

Patent: 32792
Estimated Expiration: ⤷  Try a Trial

Patent: 09923
Estimated Expiration: ⤷  Try a Trial

Malaysia

Patent: 6918
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 0725
Estimated Expiration: ⤷  Try a Trial

Patent: 11012417
Estimated Expiration: ⤷  Try a Trial

Patent: 12011171
Estimated Expiration: ⤷  Try a Trial

Patent: 12011324
Estimated Expiration: ⤷  Try a Trial

Montenegro

Patent: 294
Estimated Expiration: ⤷  Try a Trial

Patent: 846
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 6635
Estimated Expiration: ⤷  Try a Trial

Patent: 3232
Estimated Expiration: ⤷  Try a Trial

Patent: 3602
Estimated Expiration: ⤷  Try a Trial

Patent: 9926
Estimated Expiration: ⤷  Try a Trial

Peru

Patent: 130151
Estimated Expiration: ⤷  Try a Trial

Patent: 130183
Estimated Expiration: ⤷  Try a Trial

Philippines

Patent: 014502684
Estimated Expiration: ⤷  Try a Trial

Patent: 015502237
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 32792
Estimated Expiration: ⤷  Try a Trial

Patent: 52930
Estimated Expiration: ⤷  Try a Trial

Patent: 09923
Estimated Expiration: ⤷  Try a Trial

Patent: 90428
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 32792
Estimated Expiration: ⤷  Try a Trial

Patent: 52930
Estimated Expiration: ⤷  Try a Trial

Patent: 09923
Estimated Expiration: ⤷  Try a Trial

Patent: 52422
Estimated Expiration: ⤷  Try a Trial

Patent: 13337
Estimated Expiration: ⤷  Try a Trial

Patent: 90428
Estimated Expiration: ⤷  Try a Trial

San Marino

Patent: 01500285
Estimated Expiration: ⤷  Try a Trial

Patent: 01600316
Estimated Expiration: ⤷  Try a Trial

Serbia

Patent: 368
Estimated Expiration: ⤷  Try a Trial

Patent: 229
Estimated Expiration: ⤷  Try a Trial

Singapore

Patent: 6197
Estimated Expiration: ⤷  Try a Trial

Patent: 4323
Estimated Expiration: ⤷  Try a Trial

Patent: 4324
Estimated Expiration: ⤷  Try a Trial

Patent: 201500835W
Estimated Expiration: ⤷  Try a Trial

Patent: 201702025S
Estimated Expiration: ⤷  Try a Trial

Patent: 201702294Q
Estimated Expiration: ⤷  Try a Trial

Patent: 201708263S
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 32792
Estimated Expiration: ⤷  Try a Trial

Patent: 52930
Estimated Expiration: ⤷  Try a Trial

Patent: 09923
Estimated Expiration: ⤷  Try a Trial

Patent: 90428
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 1108749
Estimated Expiration: ⤷  Try a Trial

Patent: 1207799
Estimated Expiration: ⤷  Try a Trial

Patent: 1207800
Estimated Expiration: ⤷  Try a Trial

Patent: 1400249
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1599183
Estimated Expiration: ⤷  Try a Trial

Patent: 1603817
Estimated Expiration: ⤷  Try a Trial

Patent: 1715981
Estimated Expiration: ⤷  Try a Trial

Patent: 1759369
Estimated Expiration: ⤷  Try a Trial

Patent: 120034662
Estimated Expiration: ⤷  Try a Trial

Patent: 120138242
Estimated Expiration: ⤷  Try a Trial

Patent: 130064064
Estimated Expiration: ⤷  Try a Trial

Patent: 140147144
Estimated Expiration: ⤷  Try a Trial

Patent: 150043553
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 16466
Estimated Expiration: ⤷  Try a Trial

Patent: 51944
Estimated Expiration: ⤷  Try a Trial

Patent: 86821
Estimated Expiration: ⤷  Try a Trial

Patent: 38350
Estimated Expiration: ⤷  Try a Trial

Patent: 44990
Estimated Expiration: ⤷  Try a Trial

Patent: 48803
Estimated Expiration: ⤷  Try a Trial

Patent: 00773
Estimated Expiration: ⤷  Try a Trial

Patent: 27501
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 98117
Estimated Expiration: ⤷  Try a Trial

Patent: 76352
Estimated Expiration: ⤷  Try a Trial

Patent: 83692
Estimated Expiration: ⤷  Try a Trial

Patent: 98358
Estimated Expiration: ⤷  Try a Trial

Patent: 1107341
Estimated Expiration: ⤷  Try a Trial

Patent: 1136593
Estimated Expiration: ⤷  Try a Trial

Patent: 1136945
Estimated Expiration: ⤷  Try a Trial

Patent: 1139457
Estimated Expiration: ⤷  Try a Trial

Patent: 1518313
Estimated Expiration: ⤷  Try a Trial

Patent: 1704249
Estimated Expiration: ⤷  Try a Trial

Ukraine

Patent: 2959
Estimated Expiration: ⤷  Try a Trial

Uruguay

Patent: 310
Estimated Expiration: ⤷  Try a Trial

Patent: 311
Estimated Expiration: ⤷  Try a Trial

Patent: 312
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SOVALDI around the world.

Country Patent Number Title Estimated Expiration
South Korea 101599183 ⤷  Try a Trial
Brazil 112014006324 método para tratar hcv ⤷  Try a Trial
European Patent Office 3777867 COMPOSITION ET PROCÉDÉS POUR LE TRAITEMENT DU VIRUS DE L'HÉPATITE C (COMPOSITION AND METHODS FOR TREATING HEPATITIS C VIRUS) ⤷  Try a Trial
Serbia 56229 POSTUPAK ZA KRISTALIZACIJU (S)-IZOPROPIL 2-(((S)-(PERFLUOROFENOKSI)(FENOKSI)FOSFORIL)AMINO)PROPANOATA (PROCESS FOR THE CRYSTALLISATION OF (S)-ISOPROPYL 2-(((S)-(PERFLUOROPHENOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for SOVALDI

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2203462 67/2014 Austria ⤷  Try a Trial PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894 20140117
2203462 2014/065 Ireland ⤷  Try a Trial PRODUCT NAME: SOVALDI (SOFOSBUVIR); REGISTRATION NO/DATE: EU/1/13/894/001-EU/1/13/894/002 20140116
2203462 C20140035 Estonia ⤷  Try a Trial PRODUCT NAME: SOFOSBUVIIR;REG NO/DATE: EU/1/13/894 17.01.2014
2203462 92600 Luxembourg ⤷  Try a Trial PRODUCT NAME: SOVALDI (SOFOSBUVIR); AUTHORISATION NUMBER AND DATE: EU/1/13/894(001-002) - SOVALDI - SOFOSBUVIR 20140117
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.